Arcus Biosciences (RCUS) Misses Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights
August 5, 2021 4:10 PM EDTAll five clinical-stage molecules continue to advance with six ongoing randomized Phase 2 and Phase 3 studies in major tumor types, including lung, colon, prostate and pancreatic cancer AB521, a small molecule HIF-2 inhibitor, expected to enter the clinic in 4Q21 Reported encouraging results from our interim analysis for ARC-7 providing initial validation of our domvanalimab (anti-TIGIT) combinations Presented promising data at ASCO and AACR for etrumadenant (A2a/A2b adenosine receptor antagonist) in combination with other agents, providing further clinical evidence supporting the potential of this... More
